Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...
Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...
DEVASTATED Nadia Sawalha fought back tears in an emotional video as she shared some heartbreaking news. Loose Women star ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
GlobalData on MSN11d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trialDaiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback